No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BMRN Biomarin Pharmaceutical
- 84.150
- -0.870-1.02%
Close Jun 18 16:00 ET
- 83.950
- -0.200-0.24%
Post 19:02 ET
15.98BMarket Cap79.39P/E (TTM)
86.125High84.020Low2.94MVolume85.080Open85.020Pre Close249.99MTurnover1.56%Turnover Ratio96.72P/E (Static)189.88MShares99.56052wk High3.15P/B15.85BFloat Cap73.67552wk Low--Dividend TTM188.38MShs Float151.750Historical High--Div YieldTTM2.48%Amplitude3.570Historical Low85.014Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
BioMarin Presents Data Highlighting Impact Of VOXZOGO In Bone Health And Health-Related Quality Of Life In Achondroplasia At 2024 ICCBH
New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with AchondroplasiaPhase 2 and 3 Data on VOXZOGO
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO (Vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with Achondroplasia
Catalyst Watch: HP Enterprise Event, Walmart+ Week, Pure Storage Buzz, and Triple-witching Volatility
Top Gap Ups and Downs on Monday: KKR, CRWD, DEO and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion
By Josh Beckerman Shares of Texas Pacific Land and Altair Engineering reached 52-week highs on Monday after they were selected for inclusion in the S&P MidCap 400 index. Shares of Texas Pacific Land
Express News | BioMarin Pharmaceutical Shares Are Trading Higher After It Was Announced the Company Will Join the S&P MidCap 400
Comments
Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.
Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness 1
BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.
BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.
1
BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.
Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg